$6.13 -0.1 -2.2%
Last Trade - 26/02/21
| Market Cap | ÂŁ51.8m |
| Enterprise Value | ÂŁ47.8m |
| Revenue | ÂŁ4.61m |
| Position in Universe | 5267th / 6715 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st May | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 4.96 | 5.14 | 5.79 | 5.56 | 5.20 | 6.69 | 5.97 | 7.51 | +6.2% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Biomerica, Inc. is a biomedical company, which develops, manufactures, and markets medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The medical diagnostic products are sold in two markets: clinical laboratories and point of care. The diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens or other substances, which may exist in a patient’s body, stools, or blood, often in extremely small concentrations. Biomerica has developed a diagnostic guided therapy that is designed to allow physicians to identify patient-specific foods, that when removed from the diet, may alleviate or improve an individual's symptoms of Irritable Bowel Syndrome (IBS). This product is called InFoods IBS.
| Last Annual | May 31st, 2020 |
| Last Interim | November 30th, 2020 |
| Incorporated | September 22, 1971 |
| Public Since | March 23, 2009 |
| No. of Shareholders: | n/a |
| No. of Employees: | 84 |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Capital Market |
| Shares in Issue | 11,780,089 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 17571 von Karman Ave, IRVINE, 92614-6207, United States |
| Web | http://www.biomerica.com/ |
| Phone | +1 949 6452111 |
| Contact | () |
| Auditors | PKF Certified Public Accountants |
As of 26/02/21, shares in Biomerica Inc are trading at $6.13, giving the company a market capitalisation of ÂŁ51.8m. This share price information is delayed by 15 minutes.
Shares in Biomerica Inc are currently trading at $6.13 and the price has moved by 0.121k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biomerica Inc price has moved by 70.11% over the past year.
Of the analysts with advisory recommendations for Biomerica Inc, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Biomerica Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Biomerica Inc is scheduled to issue upcoming financial results on the following dates:
Biomerica Inc does not currently pay a dividend.
Biomerica Inc does not currently pay a dividend.
Biomerica Inc does not currently pay a dividend.
To buy shares in Biomerica Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Biomerica Inc are currently trading at $6.13, giving the company a market capitalisation of ÂŁ51.8m.
Here are the trading details for Biomerica Inc:
Based on an overall assessment of its quality, value and momentum, Biomerica Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Biomerica Inc are currently priced at $6.13. At that level they are trading at 77.49% discount to the analyst consensus target price of 0.00.
Analysts covering Biomerica Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.42 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biomerica Inc. Over the past six months, the relative strength of its shares against the market has been -23.97%. At the current price of $6.13, shares in Biomerica Inc are trading at -11.96% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Biomerica Inc.
Biomerica Inc's management team is headed by:
Here are the top five shareholders of Biomerica Inc based on the size of their shareholding:
